TCT

Valve-in-valve transcatheter valve replacement using Sapien XT appears to be a valuable alternative to reoperation in patients with failed aortic bioprostheses, according to 1-year results from the PARTNER II registry presented at the annual TCT Scientific Symposium.

The use of a scoring balloon plus a paclitaxel-coated balloon yielded angiographically superior results vs. a paclitaxel-coated balloon alone in patients with restenosis with limus-eluting stents, according to findings from the ISAR DESIRE 4 trial presented at the annual TCT scientific symposium.

SAN FRANCISCO — A second-generation drug-eluting bioresorbable scaffold made of magnesium alloy appears to be a feasible treatment in patients with de novo coronary artery lesions, with promising safety and performance outcomes observed at 6 months, according to study results presented at the annual TCT Scientific Symposium and published online in The Lancet.

SAN FRANCISCO — An everolimus-eluting bioresorbable scaffold demonstrated similar clinical outcomes compared with a metallic everolimus-eluting stent in the treatment of CAD, according to interim follow-up data from the ABSORB II trial presented at the annual TCT Scientific Symposium.

In patients with STEMI treated with primary percutaneous coronary intervention, undergoing PCI for chronic total occlusion within a week of STEMI appears to be safe and feasible, according to results from the EXPLORE trial presented at the annual TCT Scientific Symposium. However, PCI for CTO does not appear to improve left ventricular ejection fraction or left ventricular diastolic volume at 4 months.

Patent foramen ovale closure appears to be superior to medical management in preventing the recurrence of cryptogenic stroke, according to extended follow-up results from the RESPECT trial presented at the annual TCT Scientific Symposium. “We conclude, with this long-term, really extensive amount of new data, that treatment with the Amplatzer PFO Occluder is superior to guideline-recommended medical management,” John D. Carroll, MD, of the University of Colorado School of Medicine, said.

A uniquely-designed, sirolimus-eluting, bioresorbable stent was noninferior to an existing sirolimus-eluting stent for target lesion failure at 1 year, according to results from the PANDA III trial presented at the annual TCT Scientific Symposium. In the prospective, randomized, multicenter trial, Bo Xu, MBBS, of Fu Wai Hospital, Beijing, and colleagues enrolled 2,348 patients with symptomatic CAD, silent ischemia or ACS from 46 centers. All patients were eligible for PCI.

SAN FRANCISCO — Sanjit S. Jolly, MD, MSc, of McMaster University and the Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada offers investigator insight on the 1-year results from the TOTAL trial.

SAN FRANCISCO — Matthew J. Price, MD, an interventional cardiologist at Scripps Clinic, La Jolla, California, recaps a “vigorous debate” at the annual TCT Scientific Symposium over left atrial appendage closure with a device in patients with nonvalvular atrial fibrillation at low risk for bleeding.  

SAN FRANCISCO — An implantable mitral reconstruction device with an adjustable annuloplasty ring was found to be a feasible treatment approach for patients requiring mitral valve repair, according to data presented at the annual TCT Scientific Symposium.